Skip to main content

Table 2 Intra-cluster correlation coefficients for processes of care

From: Intra-cluster correlation coefficients in primary care patients with type 2 diabetes and hypertension

Processes of careNumber, NAverage cluster sizen (%)ICC95% CI
T2D PATIENTS WITH OR WITHOUT HYPERTENSION (N = 6722)
Test/assessment done within a specific interval
Test/assessment done on visit day
   FBG67221683053 (45.4)0.180.11, 0.25
   RBG67221682685 (39.9)0.140.08, 0.19
   Blood pressure measurement67071686574 (97.8)0.030.01, 0.05
At least 1 test/assessment within 3 months
   HbA1c67221682450 (36.4)0.090.05, 0.13
   FBG67221683797 (56.5)0.160.09, 0.22
   Foot examination (pulse, neuropathy, ulcer)67221681837 (27.3)0.170.10, 0.23
At least 1 test/assessment within 6 months
   Body mass index66961672699 (40.2)0.480.37, 0.59
At least 1 test/assessment within 12 months
   Lipid profile
    TC67221685376 (80.0)0.030.01, 0.04
    LDL-C67221684624 (68.8)0.160.10, 0.22
    HDL-C67221684614 (68.6)0.160.10, 0.23
    Triglycerides67221685300 (78.8)0.020.01, 0.04
    Complete lipid profile (TC, LDL-C, HDL-C, triglycerides)67221684533 (67.4)0.160.10, 0.22
   Serum creatinine67221685508 (81.9)0.030.01, 0.04
   Urine albumin67221683897 (58.0)0.200.13, 0.28
   Liver function67221683644 (54.2)0.370.26, 0.47
   Visual acuity examination67221683336 (49.6)0.210.13, 0.28
   Fundus examination67221682344 (34.9)0.130.08, 0.18
   Electrocardiography67221683248 (48.3)0.220.14, 0.29
Medication prescribed
Glucose-lowering drugs
   Biguanide (Metformin)67221685686 (84.6)0.010.01, 0.02
   Sulphonylurea67221683456 (51.4)0.020.01, 0.03
   Insulin67221681977 (29.4)0.020.01, 0.03
   Alpha-glucosidase inhibitor (acarbose)6722168102 (1.5)0.030.02, 0.05
Antihypertensive drugs
   ACEI/ARB67221684242 (63.1)0.040.02, 0.05
   Calcium channel blocker67221684056 (60.3)0.020.01, 0.03
   Beta-blocker67221681717 (25.5)0.030.01, 0.04
   Diuretic67221681535 (22.8)0.030.01, 0.05
   Alpha-blocker6722168380 (5.7)0.020.01, 0.03
Lipid-lowering drugs
   HMG-CoA reductase inhibitor (statin)67221685250 (78.1)0.040.02, 0.06
   Fibrate6722168164 (2.4)0.030.01, 0.04
PATIENTS WITH HYPERTENSION (N = 5014)
Test/assessment done within a specific interval
Test/assessment done on visit day
    Blood pressure measurement49851254916 (98.6)0.050.03, 0.08
At least 1 test/assessment done within 12 months
    Blood glucose tests (FBG/RBG/HbA1c)50141263590 (71.6)0.090.05, 0.13
    Serum creatinine50141264005 (79.9)0.060.03, 0.09
    Urine albumin50141262087 (41.6)0.230.15, 0.32
    Lipid profile
     TC50141263919 (78.2)0.050.03, 0.08
     LDL-C50141262954 (58.9)0.220.14, 0.30
     HDL-C50141262969 (59.2)0.210.13, 0.29
     Triglycerides50141263894 (77.7)0.050.03, 0.08
     Complete lipid profile (TC, LDL-C, HDL-C, triglycerides)50141262920 (58.2)0.210.13, 0.29
    Electrocardiography50141261802 (35.9)0.280.18, 0.37
Medication prescribed
Antihypertensive drugs
   Calcium channel blocker50141263972 (79.2)0.010.002, 0.02
   ACEI/ARB50141262210 (44.1)0.040.02, 0.06
   Beta-blocker50141261382 (27.6)0.020.01, 0.04
   Diuretic50141261054 (21.0)0.020.01, 0.03
   Alpha-blocker5014126202 (4.0)0.020.01, 0.03
Lipid-lowering drugs
   HMG-CoA reductase inhibitor50141263427 (68.3)0.040.02, 0.06
   Fibrate501412663 (1.3)0.010, 0.01
  1. ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, CI confidence interval, FBG fasting blood glucose, HbA1c glycated haemoglobin, HDL-C high-density lipoprotein cholesterol, HMG-CoA hydroxymethylglutaryl-coenzyme A, ICC intra-cluster correlation coefficient, LDL-C low-density lipoprotein cholesterol, RBG random blood glucose, T2D type 2 diabetes, TC total cholesterol